BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
BC Innovations | Jul 21, 2016
Strategy

Brexit of brains

Few in the British life sciences sector voiced support for an exit from the EU before last month's referendum, but academics, industry leaders and investors are now weighing up the actual damage as they face...
BioCentury | Jun 27, 2016
Finance

Nine lives?

Whether Circassia Pharmaceuticals plc's implosion will have a lasting effect on the U.K. biotech sector is going to be hard to tease out now that the Brexit has thrown London and the global markets into...
BioCentury | Dec 24, 2012
Strategy

The deCoding of Amgen

Most of the genomics pioneers fell short in their attempts to turn vast amounts of sequence data into drugs, as the task turned out to be far more complex than anyone imagined at the time....
BC Extra | Dec 2, 2011
Politics & Policy

EU court ruling clarifies SPCs for combo products

The EU Court of Justice issued a ruling clarifying the conditions for obtaining additional patent life for products comprising more than one active ingredient or for vaccines against multiple diseases. The case was referred to...
BC Week In Review | Jan 10, 2011
Company News

Symphogen board of directors update

Symphogen A/S , Copenhagen, Denmark   Business: Antibodies   Appointed: Goran Ando as chairman, previously CEO of Celltech Group plc , which was acquired by UCB Group  ...
BC Extra | Jan 7, 2011
Top Story

Symphogen raises EUR 100 million

Symphogen A/S (Copenhagen, Denmark) raised EUR 100 million ($132.9 million) in a series E round led by Novo A/S. New investor Danish Pension Fund PKA and existing investor Essex Woodlands Health Ventures also participated. Symphogen...
BioCentury | Dec 20, 2010
Strategy

TAP's Big Finish

It has taken nearly three decades, but ImmunoGen Inc. is finally getting some traction with its TAP targeted antibody payload platform. The company has closed out 2010 with a rush of news, and now intends...
BioCentury | Mar 8, 2010
Strategy

Merck's Chemical Test

Merck KGaA has put its own spin on the trend among mid-size European companies to choose between their prescription drugs and chemical businesses. Last week the company confirmed its commitment to a dual business strategy...
BioCentury | Jan 11, 2010
Strategy

Evolution of Biogen Idec's Pipeline

Evolution of Biogen Idec's Pipeline For the first 20 years after its formation in 1978, Biogen Inc., now called Biogen Idec Inc. (NASDAQ:BIIB), followed an opportunistic R&D strategy, with a focus on immunology. In 1999,...
Items per page:
1 - 10 of 290
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
BC Innovations | Jul 21, 2016
Strategy

Brexit of brains

Few in the British life sciences sector voiced support for an exit from the EU before last month's referendum, but academics, industry leaders and investors are now weighing up the actual damage as they face...
BioCentury | Jun 27, 2016
Finance

Nine lives?

Whether Circassia Pharmaceuticals plc's implosion will have a lasting effect on the U.K. biotech sector is going to be hard to tease out now that the Brexit has thrown London and the global markets into...
BioCentury | Dec 24, 2012
Strategy

The deCoding of Amgen

Most of the genomics pioneers fell short in their attempts to turn vast amounts of sequence data into drugs, as the task turned out to be far more complex than anyone imagined at the time....
BC Extra | Dec 2, 2011
Politics & Policy

EU court ruling clarifies SPCs for combo products

The EU Court of Justice issued a ruling clarifying the conditions for obtaining additional patent life for products comprising more than one active ingredient or for vaccines against multiple diseases. The case was referred to...
BC Week In Review | Jan 10, 2011
Company News

Symphogen board of directors update

Symphogen A/S , Copenhagen, Denmark   Business: Antibodies   Appointed: Goran Ando as chairman, previously CEO of Celltech Group plc , which was acquired by UCB Group  ...
BC Extra | Jan 7, 2011
Top Story

Symphogen raises EUR 100 million

Symphogen A/S (Copenhagen, Denmark) raised EUR 100 million ($132.9 million) in a series E round led by Novo A/S. New investor Danish Pension Fund PKA and existing investor Essex Woodlands Health Ventures also participated. Symphogen...
BioCentury | Dec 20, 2010
Strategy

TAP's Big Finish

It has taken nearly three decades, but ImmunoGen Inc. is finally getting some traction with its TAP targeted antibody payload platform. The company has closed out 2010 with a rush of news, and now intends...
BioCentury | Mar 8, 2010
Strategy

Merck's Chemical Test

Merck KGaA has put its own spin on the trend among mid-size European companies to choose between their prescription drugs and chemical businesses. Last week the company confirmed its commitment to a dual business strategy...
BioCentury | Jan 11, 2010
Strategy

Evolution of Biogen Idec's Pipeline

Evolution of Biogen Idec's Pipeline For the first 20 years after its formation in 1978, Biogen Inc., now called Biogen Idec Inc. (NASDAQ:BIIB), followed an opportunistic R&D strategy, with a focus on immunology. In 1999,...
Items per page:
1 - 10 of 290